Last reviewed · How we verify
Naltrexone Tablet and Nicotine Patch
This combination uses naltrexone to block opioid receptors and reduce cravings while nicotine patch provides nicotine replacement to support smoking cessation.
This combination uses naltrexone to block opioid receptors and reduce cravings while nicotine patch provides nicotine replacement to support smoking cessation. Used for Smoking cessation support, Nicotine dependence.
At a glance
| Generic name | Naltrexone Tablet and Nicotine Patch |
|---|---|
| Also known as | Revia and Nicotrol |
| Sponsor | The Scripps Research Institute |
| Drug class | Opioid antagonist + nicotine replacement therapy combination |
| Target | Mu-opioid receptor (naltrexone); nicotinic acetylcholine receptors (nicotine) |
| Modality | Small molecule |
| Therapeutic area | Addiction Medicine / Smoking Cessation |
| Phase | FDA-approved |
Mechanism of action
Naltrexone is an opioid antagonist that blocks mu-opioid receptors, reducing the rewarding effects of nicotine and other substances and decreasing cravings. The nicotine patch delivers steady-state nicotine transdermally to manage withdrawal symptoms and support smoking cessation. Together, they address both the pharmacological dependence and reward-seeking behavior associated with nicotine addiction.
Approved indications
- Smoking cessation support
- Nicotine dependence
Common side effects
- Nausea
- Headache
- Dizziness
- Skin irritation at patch site
- Insomnia
- Anxiety
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: